Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 (original) (raw)
Anttila MA, Kosma VM, Hongxiu J, Puolakka J, Juhola M, Saarikoski S and Syrjanen K (1999) p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer79: 1870–1878 ArticleCASPubMedPubMed Central Google Scholar
Baekelandt M, Holm R, Trope CG, Nesland JM and Kristensen GB (1999a) Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res5: 2848–2853 CASPubMed Google Scholar
Baekelandt M, Kristensen G, Nesland J, Trope C and Holm R (1999b) Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol17: 2061–2068 ArticleCASPubMed Google Scholar
Baekelandt M, Holm R, Nesland JM, Trope CG and Kristensen GB (2000) Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol22: 3775–3781 Article Google Scholar
Barlow R, Bartholomew D and Bremner J (1993) Statistical interference under order restrictions. John Wiley & Sons: London Google Scholar
Berns EM, Klijn JG, Smid M, van Staveren IL, Look MP, van Putten WL and Foekens JA (1996) TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer16: 170–179 ArticleCASPubMed Google Scholar
Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, Menghi A, Manfrin E, Bonetti F and Piubello Q (1998) bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res4: 2331–2336 CASPubMed Google Scholar
Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR and Bevilacqua G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer75: 230–235 ArticleCASPubMedPubMed Central Google Scholar
Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene13: 1971–1981 CASPubMed Google Scholar
Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M and Lohrs U (1996) bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol105: 341–349 ArticleCASPubMed Google Scholar
Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death?. Br J Cancer64: 192–196 ArticleCASPubMedPubMed Central Google Scholar
Dong Y, Walsh MD, McGuckin MA, Cummings MC, Gabrielli BG, Wright GR, Hurst T, Khoo SK and Parsons PG (1997) Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer74: 407–415 ArticleCASPubMed Google Scholar
Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther34: 155–166 ArticleCASPubMed Google Scholar
Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells2: 275–280 CASPubMed Google Scholar
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell75: 817–825 ArticleCASPubMed Google Scholar
el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE and Wang Y (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res54: 1169–1174 CASPubMed Google Scholar
EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16–17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer16: 1513–1515
Ferrandina G, Fagotti A, Salerno M, Natali P, Mottolese M, Maneschi F, Pasqua AD, Benedetti-Panici P, Mancuso S and Scambia G (1999) p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer81: 733–740 ArticleCASPubMedPubMed Central Google Scholar
Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L and Verderio P (1995) Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res1: 189–198 CASPubMed Google Scholar
Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA and Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol12: 64–69 ArticleCASPubMed Google Scholar
Henriksen R, Wilander E and Oberg K (1995) Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer72: 1324–1329 ArticleCASPubMedPubMed Central Google Scholar
Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res56: 2178–2184 CASPubMed Google Scholar
Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature348: 334–336 ArticleCASPubMed Google Scholar
Kaplan E and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc53: 457–481 Article Google Scholar
Kassim SK, Ali HS, Sallam MM, Fayed ST, Seada LS, abd-Elkawy E, Seada MA and Khalifa A (1999) Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem32: 333–338 ArticleCASPubMed Google Scholar
Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr and Berchuck A (1993) Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol81: 643–650 CASPubMed Google Scholar
Kottmeier HL (1976) Presentation of therapeutic results in carcinoma of the female pelvis: experience of the Annual Report on the Results of Treatment in Carcinoma of the Uterus, Vagina, and Ovary. Gynecol Oncol4: 13–19 ArticleCASPubMed Google Scholar
Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Whitehouse RM, Talbot DC, Gatter KC and Harris AL (1997) Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer74: 565–570 ArticleCASPubMed Google Scholar
Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K and Nagata I (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer35: 1214–1219 ArticleCASPubMed Google Scholar
Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr and Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res51: 2979–2984 CASPubMed Google Scholar
Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A, Benedetti-Panici P and Mancuso S (1998) bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res4: 517–524 CASPubMed Google Scholar
Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, Kuhn W and Schauer A (1997) Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res17: 2233–2240 CASPubMed Google Scholar
Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D and Reed JC (1995) Overexpression of the Bcl-2 protein increases the half-life of p21 Bax. J Biol Chem270: 26049–26052 ArticleCASPubMed Google Scholar
Miyashita T and Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood81: 151–157 CASPubMed Google Scholar
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene9: 1799–1805 CASPubMed Google Scholar
Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell80: 293–299 ArticleCASPubMed Google Scholar
Neijt JP, ten Bokkel Huinink WW, van der Burg ME, yan Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E and van Lent M (1991) Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer27: 1367–1372 ArticleCASPubMed Google Scholar
Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H and Tamaya T (1994) Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer70: 1191–1197 ArticleCASPubMedPubMed Central Google Scholar
Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell74: 609–619 ArticleCASPubMed Google Scholar
Oltvai ZN and Korsmeyer SJ (1994) Checkpoints of dueling dimers foil death wishes. Cell79: 189–192 ArticleCASPubMed Google Scholar
Ozols R, Rubin S and Dembo A (1992) Principles and practice of gynecologic oncology. In: Epithelial Ovarian Cancer, Hoskins W, Perez C and Young R (eds) pp 731–781. Lippincott: Philadelphia Google Scholar
Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res56: 556–562 CASPubMed Google Scholar
Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW and Vogelstein B (1994) Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res54: 3714–3717 CASPubMed Google Scholar
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res56: 689–693 CASPubMed Google Scholar
Rohlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W and Loning T (1997) p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol123: 496–501 ArticleCASPubMed Google Scholar
Schuyer M, Henzen-Logmans SC, van der Burg ME, Fieret EJ, Klijn JG, Foekens JA and Berns EM (1998) High prevalence of codon 213 ArgStop mutations of the TP53 gene in human ovarian cancer in the southwestern part of the Netherlands. Int J Cancer76: 299–303 ArticleCASPubMed Google Scholar
Skilling JS, Sood A, Niemann T, Lager DJ and Buller RE (1996) An abundance of p53 null mutations in ovarian carcinoma. Oncogene13: 117–123 CASPubMed Google Scholar
Strobel T, Swanson L, Korsmeyer S and Cannistra SA (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA93: 14094–14099 ArticleCASPubMedPubMed Central Google Scholar
Strobel T, Swanson L, Korsmeyer S and Cannistra SA (1997) Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene14: 2753–2758 ArticleCASPubMed Google Scholar
Strobel T, Kraeft SK, Chen LB and Cannistra SA (1998) BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res58: 4776–4781 CASPubMed Google Scholar
Tai YT, Lee S, Niloff E, Weisman C, Strobel T and Cannistra SA (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol16: 2583–2590 ArticleCASPubMed Google Scholar
van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG and Foekens JA (1996) Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer69: 475–479 ArticleCASPubMed Google Scholar
van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG and de Vries EG (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol13: 70–78 ArticleCASPubMed Google Scholar
Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, el-Naggar A and Press MF (1999) p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol18: 29–41 ArticleCASPubMed Google Scholar
World Health Organization (1979) WHO handbook for reporting results of cancer treatments. Vol. no. 49. World Health Organization offset publication: Geneva